The Occlutech Atrial Flow Regulator (AFR)
Product features:
The AFR is a novel cardiac implant, intended for patients who have Heart Failure with Preserved Ejection Fraction (HFpEF) or Heart Failure with Reduced Ejection Fraction (HRrEF). The AFR is a breakthrough innovation for the minimally invasive treatment of patient segments with significant unmet medical needs, or without meaningful treatment alternatives.
Occlutech has developed the AFR using its state-of-the-art nitinol braiding technology and over a decade of experience.
The AFR is a novel cardiac implant, intended for patients who have Heart Failure with Preserved Ejection Fraction (HFpEF) or Heart Failure with Reduced Ejection Fraction (HRrEF). The AFR is a breakthrough innovation for the minimally invasive treatment of patient segments with significant unmet medical needs, or without meaningful treatment alternatives.
Occlutech has developed the AFR using its state-of-the-art nitinol braiding technology and over a decade of experience.
- Implantation route and technique comparable to ASD
- High flexibility and adaptability
- Repositionable and fully retrievable
The Occlutech AFR is intended to create a permanent interatrial communication with a pre-defined diameter. The left-to-right shunt secured by the device allows blood to flow across the interatrial septum. This decompresses the left heart thus reducing debilitating symptoms of Heart Failure.
- Reduced left pressure and improved haemodynamics
- Improved quality of life and exercise capacity
- Improved NYHA Functional Class
(2019-01-09 11:07:00)
Contacts Address
MEDINT PRO a.s.Za kasarnou 1
Bratislava
831 03
Slovakia
Phones
+421 33-734-24-11+421 33-734-24-10
Email
info@medint.sk
News 01.07.2020
The BioFlo PICC is the first PICC (peripherally inserted central catheter) of its kind with Endexo T ...
09.01.2019
Product features:
The AFR is a novel cardiac implant, intended for patients who have Heart Failur ...
